Madrigal Pharmaceuticals (YDO1) Stock Statistics & Valuation Metrics
Total Valuation
Madrigal Pharmaceuticals has a market cap or net worth of EUR 8.90B. The enterprise value is EUR 15.16B.
- Market Cap
- EUR 8.90B
- Enterprise Value
- EUR 15.16B
Share Statistics
Madrigal Pharmaceuticals has 23,104,126 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 23,104,126
- Owned by Insiders
- 18.08%
- Owned by Institutions
- 37.88%
Financial Efficiency
Madrigal Pharmaceuticals’s return on equity (ROE) is -0.48 and return on invested capital (ROIC) is -31.58%.
- Return on Equity (ROE)
- -0.48
- Return on Assets (ROA)
- -0.23
- Return on Invested Capital (ROIC)
- -31.58%
- Return on Capital Employed (ROCE)
- -0.32
- Revenue Per Employee
- 1.05M
- Profits Per Employee
- -315.06K
- Employee Count
- 915
- Asset Turnover
- 0.76
- Inventory Turnover
- 0.75
Valuation Ratios
The current PE Ratio of Madrigal Pharmaceuticals is -33.39. Madrigal Pharmaceuticals’s PEG ratio is 96.72.
- PE Ratio
- -33.39
- PS Ratio
- 7.74
- PB Ratio
- 23.95
- Price to FCF
- -48.20
- Price to Operating Cash Flow
- -63.44
- PEG Ratio
- 96.72
Income Statement
In the last 12 months, Madrigal Pharmaceuticals had revenue of 958.40M and earned -288.28M in profits. Earnings per share was -12.85.
- Revenue
- 958.40M
- Gross Profit
- 902.25M
- Operating Income
- -300.10M
- Pretax Income
- -288.28M
- Net Income
- -288.28M
- EBITDA
- -264.47M
- Earnings Per Share (EPS)
- -12.85
Cash Flow
In the last 12 months, operating cash flow was -197.72M and capital expenditures -8.57M, giving a free cash flow of -206.28M billion.
- Operating Cash Flow
- -197.72M
- Free Cash Flow
- -206.28M
- Free Cash Flow per Share
- -7.08
Dividends & Yields
Madrigal Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.07%
- Earnings Yield
- -2.59%
Stock Price Statistics
- Beta
- -0.24
- 52-Week Price Change
- 4.79%
- 50-Day Moving Average
- 437.93
- 200-Day Moving Average
- 432.62
- Relative Strength Index (RSI)
- 33.62
- Average Volume (3m)
- 9
Important Dates
Madrigal Pharmaceuticals upcoming earnings date is Nov 03, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Jul 30, 2026
- Next Earnings Date
- Nov 03, 2026
- Ex-Dividend Date
- ―
Financial Position
Madrigal Pharmaceuticals as a current ratio of 4.01, with Debt / Equity ratio of 58.80%
- Current Ratio
- 4.01
- Quick Ratio
- 3.77
- Debt to Market Cap
- 0.03
- Net Debt to EBITDA
- -0.59
- Interest Coverage Ratio
- -13.45
Taxes
In the past 12 months, Madrigal Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Madrigal Pharmaceuticals EV to EBITDA ratio is -34.23, with an EV/FCF ratio of -48.47.
- EV to Sales
- 7.79
- EV to EBITDA
- -34.23
- EV to Free Cash Flow
- -48.47
- EV to Operating Cash Flow
- -50.57
Balance Sheet
Madrigal Pharmaceuticals has EUR 838.75M in cash and marketable securities with EUR 347.75M in debt, giving a net cash position of EUR 491.00M billion.
- Cash & Marketable Securities
- EUR 838.75M
- Total Debt
- EUR 347.75M
- Net Cash
- EUR 491.00M
- Net Cash Per Share
- EUR 21.25
- Tangible Book Value Per Share
- EUR 17.72
Margins
Gross margin is 91.48%, with operating margin of -25.13%, and net profit margin of -25.32%.
- Gross Margin
- 91.48%
- Operating Margin
- -25.13%
- Pretax Margin
- -25.32%
- Net Profit Margin
- -25.32%
- EBITDA Margin
- -22.75%
- EBIT Margin
- -22.87%
Analyst Forecast
The average price target for Madrigal Pharmaceuticals is EUR 615.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 615.88
- Price Target Upside
- 59.89% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 9
- Revenue Growth Forecast
- 133.47%
- EPS Growth Forecast
- 6.82%
Scores
- Smart Score
- 4
- AI Score
- ―
